Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase IV study of rozanolixizumab in Chinese adults with generalized myasthenia gravis
CTR20254130Phase 4Active
- Sponsor
- UCB
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of rozanolixizumab in myasthenia gravis (MG), sponsored by UCB. Started Dec 2025; status: active.
02
Drugs
rozanolixizumab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on CTR20254130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254130.